000952 Hubei Guangji Pharmaceutical
- 6.76
- +0.06+0.90%
Hubei Guangji Pharmaceutical News
Guangji Pharmaceutical (000952) In-depth Research: Benefiting from VB2 and VB6 Price Increases, Waiting for 2018 Results to Bloom
Comments on Guangji Pharmaceutical (000952) Annual report: the annual report is in line with expectations and looks forward to a brilliant start of 2018Q1
Guangji Pharmaceutical (000952) Annual report comment: vitamin B2 world leader waits for 2018 results to bloom in the spring
Guangji Pharmaceutical (000952) China News comments: performance is expected to improve the new chairman of the board of directors to take office soon or accelerate the reform of state-owned enterprises.
Guangji Pharmaceutical Industry (000952) China News comments: China News performance is flat and operating efficiency has been significantly improved. National reform is on the way.
Comments on the semi-annual report of Guangji Pharmaceutical Co., Ltd. (000952): VB2 continues to be strong, flexible and huge management changes demonstrate the determination to be bigger and stronger.
广济药业(000952)三季报点评：业绩提速 国企改革值得期待
【国海证券】广济药业季报点评:VB2处于景气周期业绩超预期,国改预期强烈
Comments on the Quarterly report of Guangji Pharmaceutical Co., Ltd. (000952): VB2 is in a business cycle with higher-than-expected performance and strong national reform expectations.
[Huatai] Guangji Pharmaceutical Industry: vitamin B2 boom, Q3 performance accelerated growth
Guangji Pharmaceutical (000952) Quarterly Report Review: Vitamin B2 Boom Boosts Q3 Performance Growth Accelerates
【华泰证券】广济药业:业绩环比加速增长,重申“增持”评级
广济药业(000952)公告点评：业绩环比加速增长 重申“增持”评级
广济药业(000952)公司公告点评：产品涨价 成本下降 业绩持续改善
【海通证券】广济药业公司公告点评:产品涨价,成本下降,业绩持续改善
广济药业(000952)首次覆盖报告：维生素B2景气上行 国企改革存预期
广济药业(000952)点评：VB2大金产业园停产检修 控量提价VB2价格有望继续上涨 国改预期强烈
广济药业(000952)点评：大金产业园停产检修 VB2或迎来新一轮涨价
【西南证券】广济药业:大金产业园停产检修,VB2或迎来新一轮涨价
广济药业(000952)半年报点评：VB2价格处于上涨趋势 业绩逐季向好
No Data
